Sorry, you need to enable JavaScript to visit this website.
This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the UK.
Report adverse events

Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page.

Take with ease

A small single tablet regimen (STR) with low potential for drug-drug interactions (DDIs), simple dosing and no food requirements1 

You might also like

Confidence

Prescribe with confidence

Find out if BIKTARVY® is appropriate for your patients

Learn more
Long-term health

Focus on long-term health

Understand how BIKTARVY® could impact your patient's quality of life

Learn more

Abbreviations:

3TC, lamivudine; ART, antiretroviral therapy; DDI, drug-drug interaction; FTC, emtricitabine; IV, intravenous; HBV, hepatitis B virus; HIV, human immunodeficiency virus; SmPC, Summary of Product Characteristics; STR, single-tablet regimen; TAF, tenofovir alafenamide.

References:

  1. BIKTARVY® Summary of Product Characteristics.
  2. Tenorio C, et al. HIV Glasgow 2022, 23–26 October; Glasgow, UK. Poster P058. 
  3. Dai L, et al. HIV Glasgow 2022, 23–26 October; Glasgow, UK. Oral 027.
  4. Bachelard A, et al. J Antimicrob Chemother. 2023;78:769–778.
  5. Zhang H, et al. Conference on Retroviruses and Opportunistic Infections (CROI) 2017, 13–16 February; Seattle, WA, US. Abstract 40.

UK-BVY-0703 Date of preparation February 2026